Amneal Debuts Bimatoprost 0.01% Generic in Three Sizes with $719M U.S. Sales
Amneal launched bimatoprost ophthalmic solution 0.01% in 2.5 mL, 5 mL and 7.5 mL formats, its generic equivalent to Lumigan for open-angle glaucoma and ocular hypertension. U.S. annual sales for this dosage surpassed $719 million in the 12 months ended February 2026, positioning it as a key growth driver for the Affordable Medicines segment.
1. Product Launch Details
Amneal introduced bimatoprost ophthalmic solution 0.01% in 2.5 mL, 5 mL and 7.5 mL presentations, matching the formulation of Lumigan for reducing elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
2. Market Opportunity
The generic enters a market where U.S. annual sales for bimatoprost ophthalmic solution 0.01% reached approximately $719 million in the 12 months ended February 2026, driven by an aging population and rising glaucoma prevalence.
3. Affordable Medicines Segment Growth
Building on its recent cadence of complex product introductions, this launch is expected to serve as a major growth driver for Amneal’s Affordable Medicines segment by expanding access and diversifying revenue streams.